This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert E. Anderson, MD; William Lang, MD; Stephen Shiboski, MS; Rachel Royce, MPH; Nicholas Jewell, PhD; Warren Winkelstein, Jr, MD, MPH

Arch Intern Med. 1990;150(1):73-77.

Abstract
• Serum β₂-microglobulin (β₂M) levels were measured by radioimmunoassay in 962 unmarried men recruited by probability sampling from areas in San Francisco, Calif, most severely affected by the epidemic of acquired immunodeficiency syndrome (AIDS). From July 1984 to December 1987, 65 incident AIDS cases occurred in 388 homosexual/bisexual men infected by the human immunodeficiency virus (HIV) at the time of recruitment. The mean level of β₂M in uninfected individuals at entry was 170 nmol/L. In HIV-seropositive patients who had not developed AIDS, the mean β₂M level was 254 nmol/L, and in those who had developed AIDS, the β₂M level was 347 nmol/L. After 36 months of follow-up, 34% of individuals with β₂M levels greater than 322 nmol/L at entry developed AIDS, 21% of individuals with levels between 246 and 322 nmol/L developed AIDS, while only 7.3% of those with levels below 246 nmol/L developed AIDS. The β₂M level predicted the development of AIDS independently of the CD4 lymphocyte count in HIV-seropositive individuals. Thus, 65.5% of HIV-seropositive individuals with β₂M levels above 322 nmol/L and CD4 lymphocyte counts of below 500/µL developed AIDS in 3 years. This represents an 18.4-fold increased relative hazard at 3 years over individuals with β₂M and CD4 cell counts within the reference range for uninfected individuals. A nomogram is provided that allows the easy calculation of the probability of an HIV-infected person developing AIDS in 36 months depending on prevalent levels of CD4 lymphocytes and serum β₂M.

(Arch Intern Med. 1990;150:73-77)

Author Affiliations
From the Children's Hospital of San Francisco (Calif) (Drs Anderson and Lang) and the School of Public Health, University of California, Berkeley (Mr Shiboski, Ms Royce, and Drs Jewell and Winkelstein). Dr Anderson is currently with ViRx Inc, San Francisco, Calif.

Footnotes
Accepted for publication July 14,1989.

Reprint requests to the School of Public Health, University of California, Berkeley, CA 94720 (Dr Winkelstein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Human Immunodeficiency Virus Early Intervention Physician Guidelines, Second Edition
Advisory Group on HIV Early Intervention, Second E
Arch Fam Med 1994;3:988-1002.
ABSTRACT  

CD4+ T-Lymphocyte Measures in the Treatment of Individuals Infected With Human Immunodeficiency Virus Type 1: A Review for Clinical Practitioners
Turner et al.
Arch Intern Med 1994;154:1561-1573.
ABSTRACT  

Predicting the Outcomes of Human Immunodeficiency Virus Infection: How Well Are We Doing?
Rabeneck and Wray
Arch Intern Med 1993;153:2749-2755.
ABSTRACT  

CD4 Lymphocyte Counts Within 24 Months of Human Immunodeficiency Virus Seroconversion: Findings in the US Navy and Marine Corps
Gorham et al.
Arch Intern Med 1993;153:869-876.
ABSTRACT  

Preventive Health Care for Adults With HIV Infection
Jewett and Hecht
JAMA 1993;269:1144-1153.
ABSTRACT